Global languages
2009-07-15
Regulatory

CELLAVISION AB (publ) Interim report for the period January 1 - June 30, 2009

  •    Net sales for the period amounted to SEK 42.7 million (41.3), an increase of 2 %. The second quarter accounted for SEK 20.7 million (22.8) of this amount.
  •    The operating profit for the period was SEK 1.8 million (2.8) and for the second quarter SEK 1.0 million (1.5).
  •    Earnings per share for the period amounted to SEK 0.06 (0.11).
  •    Cash and cash equivalents were SEK 9.3 million (16.9) by the end of the quarter.
  •    The new analyzer CellaVision® DM1200 was presented in Europe, and the first orders were taken.
  •    CellaVision was awarded the SwedenBIO Award for its successes during 2008.
  •    CellaVision's Japanese subsidiary received its first order.
  •    CellaVision qualified for trade on the NASDAQ OMX First North Premier.
    •  
     
      CellaVision in summary
     
     
      (MSEK)
     
     
    Jan - June 2009
    Jan - June 2008
    Full year 2008
      Net sales
    42.7
    41.3
    100.4
      Gross profit
    30.9
    25.8
    63.5
      Operating result
    1.8
    2.8
    13.4
      Net result
    1.4
    2.6
    13.1
      Cash flow
    -10.3
    0.6
    3.3
     
     
    CEO's comment
    "CellaVision's products are still receiving a great deal of attention on our main markets. The hospital market is being increasingly affected by the global financial crisis and decisions to purchase are taking longer, which is most apparent on the US market. Having said that, it is worth noting that we are still showing a positive result despite a financially unstable world market," says Yvonne Mårtensson, CEO of CellaVision.
     
    "Our new product, the CellaVision DM1200 provides CellaVision with a wider and stronger range of products, giving us a more competitive edge. The product was shown in Europe for the first time during this quarter. The analyzer was very well received and CellaVision has already taken its first orders from Sysmex in Europe. We are now waiting for the product to be ready for sale in the end of July, and the next step will be to obtain the approvals needed to sell the CellaVision DM1200 on other markets. The development of this product has demanded large resources during the period, which has contributed to the negative cash flow."
     
    "Our investments in our own sales organizations in Japan and North America have resulted in the first Japanese order received from one of Japan's largest laboratory chains as well as several important orders in Canada. North America accounted for 54 % during the period."
     
     
    For more information please contact: 
    Yvonne Mårtensson, CEO. Tel: +46 708 33 77 82, e-mail: yvonne.martensson@cellavision.com 
    Johan Wennerholm, CFO. Tel: +46 708 33 81 68, e-mail: johan.wennerholm@cellavision.com
     
     
    Download the report by pressing the link below.

    Attachments

    CellaVision AB - Interim report for the period January 1 - June 30, 2009

    Share